We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) closed at $9.63 in the latest trading session, marking a -15% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.54%. Meanwhile, the Dow gained 0.66%, and the Nasdaq, a tech-heavy index, added 0.77%.
Shares of the infectious disease drug developer have depreciated by 27% over the course of the past month, underperforming the Medical sector's loss of 8.43%, and the S&P 500's loss of 4.71%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.96 per share and a revenue of $639.74 million, indicating changes of +60% and +25.4%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Adma Biologics. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 81.9% higher. At present, Adma Biologics boasts a Zacks Rank of #1 (Strong Buy).
With respect to valuation, Adma Biologics is currently being traded at a Forward P/E ratio of 11.86. This valuation marks a discount compared to its industry average Forward P/E of 17.97.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 146, this industry ranks in the bottom 41% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade
Adma Biologics (ADMA - Free Report) closed at $9.63 in the latest trading session, marking a -15% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 0.54%. Meanwhile, the Dow gained 0.66%, and the Nasdaq, a tech-heavy index, added 0.77%.
Shares of the infectious disease drug developer have depreciated by 27% over the course of the past month, underperforming the Medical sector's loss of 8.43%, and the S&P 500's loss of 4.71%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.96 per share and a revenue of $639.74 million, indicating changes of +60% and +25.4%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Adma Biologics. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 81.9% higher. At present, Adma Biologics boasts a Zacks Rank of #1 (Strong Buy).
With respect to valuation, Adma Biologics is currently being traded at a Forward P/E ratio of 11.86. This valuation marks a discount compared to its industry average Forward P/E of 17.97.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 146, this industry ranks in the bottom 41% of all industries, numbering over 250.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.